Refined balloon pulmonary angioplasty—A therapeutic option in very elderly patients with chronic thromboembolic pulmonary hypertension. (5th May 2017)

• Record Type: Journal Article
• Authors: Roik, Marek; Wretowski, Dominik; Łabyk, Andrzej; Irzyk, Katarzyna; Lichodziejewska, Barbara; Dzikowska‐Diduch, Olga; Piotrowska‐Kownacka, Dorota; Pruszczyk, Piotr
• Is Part Of: Journal of interventional cardiology. Volume 30:Number 3(2017:Jun.)
• Page Start: 249
• Page End: 255
• Publication Date: 2017-05-05
• Subjects: chronic thromboembolic pulmonary hypertension -- efficacy -- elderly -- refined balloon pulmonary angioplasty -- safety -- therapeutic; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.1206
• DOI: 10.1111/joic.12387
• Languages: English
• ISSNs: 0896-4327

Abstract

Abstract : Introduction/Objectives: Balloon pulmonary angioplasty (BPA) is a developing treatment for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, to our knowledge there are no published data on BPA in CTEPH subjects aged 75 or over. The aim of the study was to analyze clinical and hemodynamic outcomes of sequential BPA in very elderly patients disqualified from pulmonary endarterectomy (PEA). Patients and Methods: We enrolled 10 patients (4 male, 6 female, median age 81 [75‐88]) with confirmed CTEPH, mPAP > 30 mmHg, and WHO class > II, disqualified from PEA. Overall, 10 patients underwent 39 BPA sessions (mean 3.9 sessions per patient, range 1‐9), and 70 pulmonary arteries were dilated, (mean 6.5 vessels per patient, range 1‐14). Results: Pulmonary angioplasty resulted in significant clinical and hemodynamic improvement in every patient: 6 MWT distance increased from a median of 221 m (80‐320) to 345 (230‐455) and plasma NT‐proBNP levels decreased ( P < 0.01). Sequential BPA resulted in normalization of mPAP (<25 mmHg) in 6 of 10 patients and mPAP decreased to 25‐30 mmHg in three others. In the whole group mPAP decreased from 41 (31‐53) mmHg to 23 (17‐33) mmHg ( P < 0.01). Overall, mean PAP and PVR decreased significantly in all cases, while CO and CI increased ( P < 0.01). No severe complications occurred during BPA and over a median follow‐up of 553 days (range 81‐784), and all patients are still alive and in good general health. Conclusion: This study demonstrated the safety and efficacy of refined BPA in CTEPH patients aged 75 or over, disqualified from PEA. Refined BPA may emerge as an alternative therapeutic strategy in very elderly CTEPH patients who are suitable for surgery, but this requires further validation in a large prospective study.